(RTTNews) - Corvus Pharmaceuticals Inc. (CRVS), a clinical-stage biopharmaceutical company, is scheduled to announce interim data from its Phase 1 trial of Soquelitinib in moderate to severe atopic dermatitis today, December 18, 2024.
Soquelitinib (formerly known as CPI-818) is an investigational small molecule drug given orally designed to selectively inhibit ITK (interleukin-2-inducible T cell kinase). ITK is an enzyme that is expressed predominantly in T cells and plays a role in T cell and natural killer (NK) cell immune function.
The phase I trial of Soquelitinib is designed to enroll 64 patients who have failed at least one prior therapy. Four different 28-day dosing regimens of Soquelitinib are evaluated against a placebo group in the study. The endpoints include safety and improvement in the Eczema Area and Severity Index.
Corvus will host a conference call and webcast today December 18, 2024, at 8:00 a.m. ET / 5:00 a.m. PT to discuss the atopic dermatitis trial data.
CRVS closed Tuesday's (Dec.17.2024) trading at $7.39, up 7.10%. In after-hours trading, the stock was up nearly 22% at $9.00.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
%20Q3%20Earnings%20Disappoint%20as%20Budget%20Tightens%3F%20-%20Analyst%20Blog%20%7C%20Nasdaq&_biz_n=7&rnd=717123&cdn_o=a&_biz_z=1743335762199)
